Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADSTEM Inj. in Moderate to Severe Atopic Dermatitis
NCT02888704Phase 1Completed
- Sponsor
- EHL Bio Co., Ltd.
- Start
- Jul 2016
- Primary completion
- Dec 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ADSTEM in atopic dermatitis (AD) (2 arms), sponsored by EHL Bio Co., Ltd. Primary endpoint: Number of subjects with treatment-related adverse events at 12 weeks. Started Jul 2016; status: completed.
02
Drugs
ADSTEM
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02888704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02888704.